在线办公
期刊论坛
主 管
中国人民解放军总医院
主 办
中国人民解放军总医院老年心血管病研究所
中国科技出版传媒股份有限公司
编 辑
中华老年多器官疾病杂志编辑委员会
100853, 北京市复兴路28号
电话:010-66936756
传真:010-66936756
E-mail: zhlndqg@mode301.cn
创刊人 王士雯
总编辑 范利
副总编辑 陈韵岱
执行主编 叶大训
编辑部主任 王雪萍
ISSN 1671-5403
CN 11-4786
创刊时间 2002年
出版周期 月刊
邮发代号 82-408
友情链接
郭欣,李玉超,刘震宇.氟哌噻吨美利曲辛片对慢性阻塞性肺疾病合并焦虑抑郁症状患者的临床影响[J].中华老年多器官疾病杂志,2019,18(7):523~526
氟哌噻吨美利曲辛片对慢性阻塞性肺疾病合并焦虑抑郁症状患者的临床影响
Clinical effect of flupentixol/melitracen tablets on chronic obstructive pulmonary disease patients with symptoms of anxiety and depression
投稿时间:2019-03-23  
DOI:10.11915/j.issn.1671-5403.2019.07.111
中文关键词:  慢性阻塞性肺疾病;焦虑;抑郁
英文关键词:chronic obstructive pulmonary disease; anxiety; depression
基金项目:
作者单位E-mail
郭欣 解放军9660 5 部队医院 呼吸内科,通化 134000 18504455799@163.com 
李玉超 解放军9660 5 部队医院 呼吸内科,通化 134000  
刘震宇 解放军9660 5 部队医院神经内科,通化 134000  
摘要点击次数: 141
全文下载次数: 146
中文摘要:
      目的 研究黛力新(氟哌噻吨美利曲辛片)对慢性阻塞性肺疾病(COPD)合并抑郁焦虑症状患者的临床影响。方法 选取2018年1月至2019年1月在解放军96605部队医院呼吸内科住院治疗的COPD合并焦虑和(或)抑郁患者共128例为研究对象。分为2组:黛力新组和对照组,每组64例。对照组患者给予COPD规范化治疗;黛力新组在对照组基础上每天清晨口服黛力新。治疗4周后,对比2组患者治疗前后汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)、临床症状和改良版英国医学研究会呼吸困难量表(mMRC)评分,以及1s用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1占预计值百分比(FEV1% pred)和FEV1/FVC等肺功能检查指标。采用SPSS 19.0软件进行数据处理。依据数据类型,组间比较分别采用t检验或χ2检验。结果 128例患者焦虑合并抑郁47例,单独焦虑57例,单独抑郁24例。治疗后黛力新组患者的HAMA[(6.1±1.3) vs(10.7±1.9)]、HAMD[(7.6±1.7) vs(9.7±2.0)]、症状[(3.2±1.3) vs(6.0±1.7)]和mMRC[(1.1±0.7) vs(1.9±0.4)]评分均显著低于对照组,而FEV1/FVC[(78.3±3.9)% vs(67.9±4.4)%]显著高于对照组,差异均具有统计学意义(P<0.05)。结论 黛力新能有效缓解COPD患者焦虑抑郁症状和改善患者的生活质量。
英文摘要:
      Objective To determine the clinical efficacy of flupentixol/melitracen tablets (deanxit tablets) on chronic obstructive pulmonary disease(COPD) patients accompanied with depression and anxiety symptoms. Methods A total of 128 COPD patients with symptoms of anxiety and/or depression in our department from January 2018 to January 2019 were recruited in this study. They were divided into the deanxit group and control group. The patients of the control group only received conventional COPD treatment, while those of the treatment group were given oral administration of deanxit in every morning besides conventional treatment for COPD. After 4 weeks, Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD), clinical symptoms and modified British medical research council scale (mMRC) were used to survey their mental and physical conditions before and after treatment. Pulmonary function parameters, such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1 as a percentage of predicted value (FEV1% pred), and ratio of FEV1 to FVC (FEV1/FVC) were also measured. The results were compared before and after treatment, and between the 2 groups. SPSS statistics 19.0 was used to perform the statistical analysis. Student′s t test or Chi-square test was employed for comparison between the groups in different data types. Results Among 128 patients, 47 patients had anxiety and depression, 57 patients had anxiety alone and 24 patients had depression alone. Compared with the control group, the deanxit group had significantly lower HAMA score [(6.1±1.3) vs (10.7±1.9)], HAMD score [(7.6±1.7) vs (9.7±2.0)], clinical symptoms score [(3.2±1.3) vs (6.0±1.7)] and mMRC score [(1.1±0.7) vs (1.9±0.4)], but obviously higher FEV1/FVC [(78.3±3.9)% vs (67.9±4.4)%] (all P<0.05). Conclusion Deanxit effectively relieves anxiety and depression symptoms and improves the quality of life in the COPD patients.
查看全文    下载PDF阅读器
关闭